Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...

Researchers Uncover Mechanism That Fuels Growth of Aggressive B-Cell Lymphoma June 18 ... Details About Rare Second Cancers Related to CAR-T Therapy June 12, 2024 — A new detailed analysis ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Peripheral T-cell lymphomas are a rare and heterogeneous type of lymphoma, with geographical and ethnic variations in histological subtypes that differ across the world.1 In The Lancet Haematology, ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

Lymphoma causes symptoms of organ failure before death. Learn what patients in palliative or hospice care could experience ...